2-(3-히드록시프로폭시)-1,25-디히드록시비타민D3

한글명:2-(3-히드록시프로폭시)-1,25-디히드록시비타민D3

카스 번호104121-92-8

상품명:2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3

CBNumberCB71319007

분자식C30H50O5

포뮬러 무게490.71

MOL 파일104121-92-8.mol

동의어(한글)

2-(3-히드록시프로폭시)-1,25-디히드록시비타민D3

화학적 성질

녹는점	126-128℃
끓는 점	655.7±55.0 °C(Predicted)
밀도	1.10
저장 조건	Store at -20°C
용해도	DMSO에 용해됨
물리적 상태	가루
산도 계수 (pKa)	13.80±0.60(Predicted)
색상	White to off-white
InChIKey	FZEXGDDBXLBRTD-AYIMTCTASA-N
SMILES	[C@@H]1(O)C/C(=C/C=C2\CCC[C@@]3(C)[C@@]\2([H])CC[C@@H]3[C@H](C)CCCC(O)(C)C)/C(=C)[C@@H](O)[C@@H]1OCCCO

2-(3-히드록시프로폭시)-1,25-디히드록시비타민D3 화학적 특성, 용도, 생산

개요
Eldecalcitol (Edirol) was approved in January 2011 by the Japanese Ministry of Health, Labor, and Welfare for the treatment of osteoporosis. Because of vitamin D’s central role in the bone health, vitamin D and analogs of vitamin D have been used to treat patients diagnosed with osteoporosis. Eldecalcitol is an analog of the active form of vitamin D, calcitriol, in which the lower cyclohexane ring contains a hydroxypropyl group. The synthesis of eldecalcitol involves the assembly of two units, a fully protected (3S,4S,5R)-oct-1-en-7-yne-3,4,5-triol and a fused bicyclic system, (R)-6- ((1R,3aR,7aR,E)-4-(bromomethylene)-7a-methyloctahydro-1H-inden-1- yl)-2-methylheptan-2-ol, through a Diels-Alder reaction to give fully protected eldecalcitol. The hydroxyl groups are then deprotected to give the parent molecule. Eldecalcitol binds to the vitaminDreceptor 2.7-fold more potently than calcitriol, while only weakly inhibiting serum parathyroid hormone.
용도
Eldecalcitol is a derivative of vitamin D3 (V676045) which is the vitamin that mediates intestinal calcium absorbtion, bone calcium metabolism and probably, muscle activity.
정의
ChEBI: A hydroxycalciol that is calcitriol with a 3-hydroxypropoxy group at position 2.
Clinical Use
Eldecalcitol is a vitamin D3 analog approved in Japan for the treatment of osteoporosis. Itwasdiscoveredby Chugai and co-developed with Taisho. Eldecalcitol, a hormonally active calcitrol analog, regulates calcium and bone metabolism. The drug was approved on the basis of results from randomized, double-blinded, parallelgroup, phase III studies taking place over three years that showed eldecalcitol to significantly lower incidence of new vertebral fractures compared to those receiving the comparator drug alfacalcidol. Discovery and SAR studies of vitamin D3 analogs leading to the identification of eldecalcitol have been reported. In addition, multiple syntheses, including parallel approaches, have been reported in publications and patents.

2-(3-히드록시프로폭시)-1,25-디히드록시비타민D3 공급 업체

Send Inquriy